At Ketavita Wellness Clinic, we offer specialized treatments for refractory chronic migraine that hasn’t responded adequately to traditional approaches. When conventional migraine medications including triptans, preventive medications, and other standard therapies haven’t provided sufficient relief, our IV ketamine therapy and FDA-approved TMS offer different mechanisms that target central pain processing, neural sensitization, and migraine attack generation.
Located in Wyckoff, New Jersey, our clinic provides evidence-based care from experienced medical professionals who understand how disabling chronic migraine can be. We create personalized treatment protocols designed to help you achieve meaningful reduction in migraine frequency, severity, and impact on your quality of life.
Every treatment journey begins with a comprehensive evaluation where we review your migraine history including headache frequency and duration, typical pain severity and characteristics, accompanying symptoms like nausea, light sensitivity, or aura, triggers you’ve identified, previous treatments tried including acute and preventive medications, how migraines affect your work, relationships, and daily functioning, and whether you meet criteria for refractory chronic migraine. We work closely with you throughout treatment, monitoring your response and adjusting protocols to optimize outcomes.
Migraines are a neurological disorder affecting approximately 12% of the population worldwide, making it the second leading cause of disability globally. Chronic migraine, defined as headaches occurring 15 or more days per month for at least three months with at least eight days per month meeting migraine criteria, affects approximately 2% of the population and causes particularly severe disability.
Migraine headaches differ significantly from typical tension headaches. They typically present as moderate to severe throbbing or pulsating pain, often on one side of the head, though pain can be bilateral. Attacks last 4-72 hours when untreated and are accompanied by additional symptoms including nausea or vomiting, sensitivity to light (photophobia), sensitivity to sound (phonophobia), and worsening with routine physical activity.
Many people with migraine experience aura—temporary neurological symptoms that typically precede the headache phase. Visual auras are most common, including seeing flashing lights, zigzag patterns, or temporary vision loss. Other auras involve sensory changes like tingling or numbness, speech difficulties, or other neurological symptoms. Aura typically develops gradually over 5-20 minutes and lasts less than 60 minutes.
The impact of chronic migraine extends far beyond physical pain. Frequent severe headaches significantly impair work productivity, with many people unable to work during attacks. Social and family relationships suffer as people cancel plans or miss important events. Anxiety develops around when the next attack will occur. Depression is common, partly from the chronic nature of the condition and partly from biological factors. Quality of life becomes severely diminished as life revolves around managing and avoiding migraines.
Refractory chronic migraine represents the most challenging presentation. This occurs when chronic migraine persists despite appropriate trials of multiple preventive medications, acute treatments, and other standard therapies. People with refractory migraine continue to experience frequent, disabling headaches that severely limit their functioning despite trying treatments that help many others.
Migraine involves complex changes in brain function and pain processing. Modern research shows migraine is a neurological disorder involving altered brain excitability, abnormal sensory processing, and dysfunction of pain-modulating systems rather than simply a vascular headache as once thought.
Central sensitization plays an important role in chronic migraine. With repeated migraine attacks, the nervous system becomes increasingly sensitive to pain signals. Neurons involved in processing pain become hyperexcitable, amplifying sensory input and lowering the threshold for triggering migraine attacks. This progressive sensitization helps explain why episodic migraine can transform into chronic daily headache in some individuals.
Glutamate neurotransmission through NMDA receptors contributes to this sensitization process. During migraine attacks, glutamate levels increase in pain-processing regions of the brain. Excessive glutamate activity through NMDA receptors amplifies pain signals and contributes to the maintenance of central sensitization. This NMDA-mediated process represents a potential treatment target distinct from conventional migraine medications.
Cortical spreading depression—a wave of neuronal and glial depolarization that spreads across the cortex—is thought to underlie migraine aura and may trigger the headache phase. This phenomenon involves dramatic changes in brain metabolism, blood flow, and inflammatory mediator release. Understanding these mechanisms has led to exploration of treatments targeting neural excitability and glutamate systems.
Additional mechanisms include dysfunction of brainstem pain-modulating circuits, activation of the trigeminovascular system causing neurogenic inflammation around blood vessels, and imbalances in neurotransmitters including serotonin. The complexity and multifactorial nature of migraine explain why no single treatment works for everyone and why some migraines prove refractory to standard approaches.
Ketavita Wellness Clinic offers advanced treatments for refractory chronic migraine:
IV Ketamine Therapy delivers ketamine through extended intravenous infusions, typically 2-4 hours in duration. Ketamine works as an NMDA receptor antagonist, targeting central sensitization and glutamate-mediated processes involved in chronic migraine. Research suggests ketamine may provide both immediate pain relief and longer-term reductions in headache frequency through neuroplastic effects on sensitized pain circuits.
TMS Therapy is FDA-cleared for acute treatment of migraine with aura and prophylactic (preventive) treatment of migraine headache. This non-invasive treatment uses single-pulse transcranial magnetic stimulation to interrupt cortical spreading depression—the neurological phenomenon underlying migraine aura and potentially triggering the headache phase. TMS doesn’t require medication or anesthesia, and many insurance plans cover treatment for eligible patients.
During your consultation, we’ll discuss which treatment approach may be most appropriate based on your migraine characteristics, previous treatment history, and whether you primarily need acute attack relief, preventive treatment, or both.
Ketamine functions as a noncompetitive antagonist of NMDA receptors, blocking excessive glutamatergic signaling implicated in migraine pathophysiology. By antagonizing NMDA receptors, ketamine may interrupt central sensitization processes that maintain chronic migraine and lower the threshold for attack generation.
The NMDA receptor antagonism produces several potentially beneficial effects for migraine. First, ketamine may reduce cortical hyperexcitability, potentially affecting the generation of cortical spreading depression underlying migraine aura and attack initiation. Second, by blocking NMDA-mediated glutamate transmission, ketamine interrupts pain amplification in central pain-processing pathways, potentially reducing headache severity during attacks.
Third, ketamine promotes neuroplasticity through increased brain-derived neurotrophic factor and synaptic remodeling. These neuroplastic effects may help reverse maladaptive neural changes associated with chronic migraine, potentially providing sustained benefits beyond immediate pain relief. The ability to “reset” sensitized pain circuits distinguishes ketamine from conventional acute migraine treatments.
Additionally, ketamine affects other systems relevant to migraine beyond NMDA receptors, including anti-inflammatory effects that may reduce neurogenic inflammation, effects on brainstem pain-modulating circuits, and interactions with other neurotransmitter systems involved in migraine pathophysiology.
Research on ketamine for migraine includes both acute treatment of migraine attacks and longer-term treatment of refractory chronic migraine. Some studies show rapid pain relief during acute attacks, while case series examining repeated infusions for chronic refractory migraine suggest sustained reductions in headache frequency and severity in some patients. The mechanism may involve both immediate pain relief and longer-term disease-modifying effects through neuroplasticity.
Your migraine treatment journey at Ketavita begins with a thorough evaluation. We’ll discuss your migraine characteristics in detail including headache frequency (days per month with headache), typical attack duration, pain severity and quality, location of pain, accompanying symptoms like nausea, photophobia, phonophobia, presence and type of aura if applicable, and what percentage of headaches meet full migraine criteria versus probable migraine or tension-type headache.
Understanding your treatment history is essential: all acute medications tried including triptans, NSAIDs, antiemetics, their effectiveness and tolerability; all preventive medications tried including beta-blockers, anticonvulsants, antidepressants, CGRP monoclonal antibodies, Botox, their doses, duration of trials, and outcomes; other interventions like nerve blocks, devices, or behavioral treatments; and current medication regimen. This comprehensive assessment helps determine if you meet criteria for refractory chronic migraine and whether ketamine therapy is appropriate.
For IV ketamine therapy for migraine, treatment protocols may vary based on whether the goal is acute attack treatment or longer-term management of chronic refractory migraine. Protocols for chronic refractory migraine typically involve extended infusion times—often 2-4 hours—over a series of treatments. Some centers use gradually escalating doses across multiple days of intensive treatment.
During each session, you’ll receive your ketamine infusion while resting in a private, comfortable treatment room. We monitor your vital signs continuously throughout the infusion. You may experience dissociative effects during treatment—feelings of detachment, altered perception, or mild euphoria—but these are temporary and typically resolve within 1-2 hours after the infusion ends.
Common side effects are generally mild and transient including temporary dissociative feelings during and shortly after infusion, dizziness or lightheadedness, mild nausea (which can be challenging given migraine-associated nausea), brief changes in perception, drowsiness, and temporary blood pressure elevation. These effects are short-lasting and resolve after treatment completion.
After each treatment session, you’ll spend additional time in our office for recovery and monitoring before leaving. You cannot drive for 24 hours after ketamine treatment and must bring someone to drive you home.
Response to ketamine therapy for migraine varies significantly among individuals. Research on refractory chronic migraine shows some patients experience substantial reductions in headache frequency and severity, with effects potentially lasting weeks to months after treatment series. Other patients show minimal response. Factors predicting response aren’t fully understood. We track your individual response using headache diaries and standardized migraine disability assessments to determine treatment effectiveness.
Ketamine therapy for migraine may be appropriate if you have chronic migraine that has proven refractory to standard treatments. You may be a candidate if you experience headaches 15 or more days per month with at least 8 days meeting migraine criteria, have tried and failed adequate trials of at least two different preventive medication classes, have tried appropriate acute treatments without adequate control, continue to have severe disability from frequent migraines despite treatment, and meet criteria for refractory chronic migraine.
Good candidates for ketamine therapy are adults with refractory chronic migraine who remain severely disabled despite appropriate trials of conventional treatments. Research on ketamine for migraine has focused primarily on this refractory population rather than episodic migraine or first-line treatment.
Certain factors may affect treatment suitability. During evaluation, we review cardiovascular health (ketamine temporarily raises blood pressure), history of psychiatric conditions including psychosis, substance use history including any history of medication overuse headache, current medications including those that might interact with ketamine, and complete medical and headache history. Your full evaluation helps ensure safe, appropriate treatment.
It’s important to understand that ketamine therapy for migraine represents off-label use. The evidence base is more limited than for some other ketamine applications, with most data coming from case series and retrospective studies rather than large randomized controlled trials. Some studies show benefit while others show mixed results. We discuss current research findings transparently during consultation so you can make fully informed treatment decisions about this emerging treatment approach.
Our ketamine protocols for refractory chronic migraine are informed by available research from specialized headache centers. Case series and retrospective studies suggest that some patients with refractory chronic migraine experience meaningful reductions in headache frequency, severity, and associated disability following ketamine treatment series. Response rates vary across studies, with some centers reporting 70-80% of patients experiencing some degree of benefit.
Safety is paramount in all our treatments. Ketamine has been used safely in medical settings for decades, and we follow established safety protocols for subanesthetic dosing. All treatments are administered by licensed medical professionals with appropriate training, monitoring equipment, and emergency protocols.
We recognize that effective migraine management requires comprehensive, multidisciplinary treatment. While ketamine may provide benefit for some patients with refractory chronic migraine, we strongly encourage continued engagement with comprehensive migraine care including appropriate preventive and acute medications, identification and management of triggers, behavioral interventions including stress management and sleep hygiene, treatment of comorbid conditions like depression or anxiety, and regular follow-up with headache specialists.
Ketamine should be viewed as one potential option for refractory chronic migraine rather than a first-line treatment or cure. Chronic migraine typically requires ongoing, multifaceted management, and optimal outcomes come from combining various therapeutic approaches tailored to your specific headache pattern and treatment response.
Patient education is essential to our approach. We ensure you understand how ketamine works differently from conventional migraine treatments, what the current research shows including limitations of available evidence, realistic expectations given individual variability in response, potential side effects or risks, and how ketamine fits into comprehensive migraine management. Informed patients with realistic expectations are better positioned to make appropriate treatment decisions.
Ketamine therapy for migraine is typically not covered by insurance as it represents off-label use. We provide transparent pricing information during your consultation so you can make informed decisions about treatment.
IV ketamine therapy for chronic pain conditions including refractory chronic migraine is $1,000 per session. Treatment protocols for chronic refractory migraine typically involve multiple infusions over several weeks, with the specific number based on individual response and established protocols.
The total investment depends on your treatment protocol, whether you respond favorably to treatment, and whether maintenance sessions are needed. Given the variability in response and limited long-term outcome data, we discuss expected treatment course and realistic outcome expectations during your consultation.
We understand that cost is a significant consideration, especially after already trying multiple expensive migraine treatments without success. However, patients with refractory chronic migraine who respond favorably to ketamine treatment may experience substantial improvements in headache frequency, severity, and disability that significantly enhance quality of life and ability to function, work, and engage in daily activities.
While insurance typically doesn’t cover ketamine therapy for migraine, we can provide receipts and clinical documentation that you may submit to your insurance company for possible out-of-network reimbursement. For an additional $50 fee, we can prepare detailed documentation for insurance submission. Coverage decisions are made by individual insurance companies based on their policies, and approval is not guaranteed.
If you’ve been struggling with chronic migraine despite trying multiple conventional treatments, IV ketamine therapy at Ketavita Wellness Clinic may be worth considering. Our approach provides a treatment option through NMDA receptor antagonism that works differently than standard migraine medications for patients with refractory disease.
Schedule a consultation to discuss your chronic migraine history and treatment trials, review whether you meet criteria for refractory chronic migraine, explore whether ketamine therapy might be appropriate for your situation, and develop a personalized treatment plan if you proceed with treatment.
Living with refractory chronic migraine is profoundly disabling, but emerging treatment options continue to develop. Contact us today to learn whether ketamine therapy might be appropriate for your refractory migraine.
Response varies significantly among individuals. Case series from specialized headache centers report that approximately 70-80% of patients with refractory chronic migraine experience some degree of benefit, though response magnitude varies. Some patients experience substantial reductions in headache frequency and severity, while others show minimal response. Evidence comes primarily from case series and retrospective studies rather than large controlled trials.
Ketamine has been studied for both acute attack treatment and longer-term management of chronic refractory migraine. Our protocols focus on treatment of chronic refractory migraine with the goal of reducing overall headache frequency and severity rather than treating individual acute attacks.
Duration varies among individuals who respond to treatment. Some patients experience sustained benefit lasting weeks to months after a treatment series. Others may require periodic maintenance treatments. Individual response patterns help guide maintenance scheduling.
Research and clinical use have focused primarily on refractory chronic migraine—frequent headaches that persist despite appropriate trials of multiple preventive and acute treatments. This represents the most challenging migraine population with greatest disability and need for alternative treatments.
Protocols vary but typically involve a series of infusions over several weeks. The specific number depends on the protocol used and your individual response. Some centers use intensive multi-day protocols while others use weekly infusions over several weeks.
Yes, typically. Most patients continue their current preventive and acute migraine medications during ketamine treatment. We’ll review all your medications during consultation to ensure there are no contraindications. Never discontinue migraine medications without consulting your prescribing physician.
No. Ketamine is not a cure for chronic migraine. It’s a treatment that may provide meaningful reduction in headache frequency and severity for some patients with refractory disease, potentially improving quality of life and function. Chronic migraine typically requires ongoing management with multiple treatment approaches.
Side effects are generally mild and short-lasting, occurring during or shortly after infusion. Common effects include temporary dissociative feelings, dizziness, mild nausea, brief changes in perception, and drowsiness. These typically resolve within 1-2 hours after infusion completion.
The evidence base is developing but more limited than for some other ketamine applications. Most data comes from case series, retrospective studies, and smaller trials rather than large randomized controlled trials. Some studies show benefit while others show mixed results. We discuss current evidence limitations during consultation.
Pain Management
Conditions Treated
365 Franklin Avenue, Wyckoff, NJ 07481